Representative examples of agents that can be considered for further investigation as maintenance therapy after hematopoietic-cell transplantation.
| Disease . | Agent . |
|---|---|
| Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leumkeima; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma | |
| ALL (Ph+) | Imatinib, dasatinib, nilotinib |
| AML (FLT3+) | Lestaurtinib |
| CLL | Rituximab, alemtuzumab |
| CML | Imatinib, dasatinib, nilotinib |
| MDS | Decitabine, 5-azacytidine, lenalidomide |
| Mutliple myeloma | Thalidomide, lenalidomide, bortezomib |
| Myelofibrosis | JAK2 inhibitors |
| NHL | Rituximab, alemtuzumab |
| Disease . | Agent . |
|---|---|
| Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leumkeima; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma | |
| ALL (Ph+) | Imatinib, dasatinib, nilotinib |
| AML (FLT3+) | Lestaurtinib |
| CLL | Rituximab, alemtuzumab |
| CML | Imatinib, dasatinib, nilotinib |
| MDS | Decitabine, 5-azacytidine, lenalidomide |
| Mutliple myeloma | Thalidomide, lenalidomide, bortezomib |
| Myelofibrosis | JAK2 inhibitors |
| NHL | Rituximab, alemtuzumab |